NCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancer
08/2023
Journal Article
Authors:
Kennecke, H. F.;
Auer, R.;
Cho, M.;
Dasari, N. A.;
Davies-Venn, C.;
Eng, C. ;
Dorth, J.;
Garcia-Aguilar, J.;
George, M.;
Goodman, K. A.;
Kreppel, L.;
Meyer, J. E.;
Monzon, J.;
Saltz, L.;
Schrag, D.;
Smith, J. J.;
Zell, J. A.;
Das, P.;
National Cancer Institute Rectal-Anal Task, Force
Volume:
115
Pagination:
1457-1464
Issue:
12
Journal:
J Natl Cancer Inst
PMID:
37535679
URL:
https://www.ncbi.nlm.nih.gov/pubmed/37535679
Keywords:
United States Humans Consensus National Cancer Institute (U.S.) *Rectal Neoplasms/pathology Chemoradiotherapy Neoadjuvant Therapy
Abstract:
The optimal management of locally advanced rectal cancer is rapidly evolving. The National Cancer Institute Rectal-Anal Task Force convened an expert panel to develop consensus on the design of future clinical trials of patients with rectal cancer. A series of 82 questions and subquestions, which addressed radiation and neoadjuvant therapy, patient perceptions, rectal cancer populations of special interest, and unique design elements, were subject to iterative review using a Delphi analytical approach to define areas of consensus and those in which consensus is not established. The task force achieved consensus on several areas, including the following: 1) the use of total neoadjuvant therapy with long-course radiation therapy either before or after chemotherapy, as well as short-course radiation therapy followed by chemotherapy, as the control arm of clinical trials; 2) the need for greater emphasis on patient involvement in treatment choices within the context of trial design; 3) efforts to identify those patients likely, or unlikely, to benefit from nonoperative management or minimally invasive surgery; 4) investigation of the utility of circulating tumor DNA measurements for tailoring treatment and surveillance; and 5) the need for identification of appropriate end points and recognition of challenges of data management for patients who enter nonoperative management trial arms. Substantial agreement was reached on priorities affecting the design of future clinical trials in patients with locally advanced rectal cancer.
